Potent antitumour activity of a new class of tumour-specific killer cells

Si.-Yi Chen, An-Gang Yang, Ji-Dai Chen, Timothy Kute, C. Richter King, John Collier, Yanping Cong, Changping Yao and Xue F. Huang
Additional contact information
Si.-Yi Chen: Comprehensive Cancer Center, Bowman Gray School of Medicine, Wake Forest University
An-Gang Yang: Comprehensive Cancer Center, Bowman Gray School of Medicine, Wake Forest University
Ji-Dai Chen: Comprehensive Cancer Center, Bowman Gray School of Medicine, Wake Forest University
Timothy Kute: Comprehensive Cancer Center, Bowman Gray School of Medicine, Wake Forest University
Yanping Cong: Comprehensive Cancer Center, Bowman Gray School of Medicine, Wake Forest University
Changping Yao: Comprehensive Cancer Center, Bowman Gray School of Medicine, Wake Forest University
Xue F. Huang: Comprehensive Cancer Center, Bowman Gray School of Medicine, Wake Forest University

Nature, 1997, vol. 385, issue 6611, 78-80

Abstract: Abstract Two approaches to the antibody-directed targeting of toxic or cytolytic activity and augmentation of cellular immune responses have been explored for tumour immunotherapy, but so far success has been limited1–3. Obstacles facing immunotherapy are the limited accessibility of antibodies or antibody conjugates to solid tumours and the difficulty in obtaining tumour-specific cytotoxic lymphocytes4–7. Here we generate a new class of tumour-specific killer cells by genetically modifying lymphocytes to produce and secrete a targeted toxin against an oncoprotein overexpressed on breast and other tumour cells. The transduced lymphocytes were shown to have potent and selective cytotoxicity to tumours in culture and nude mouse models. The potent in vivo antitumour activity is probably a result of the migration of the lymphocytes to tumours as a targeted toxin carrier, and production and accumulation of the targeted toxins inside tumours as a producer. Our approach, which has features of both antibody-directed and cell-mediated immunotherapy, may have application in a gene therapy context.

Date: 1997
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/385078a0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:385:y:1997:i:6611:d:10.1038_385078a0

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/385078a0

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().